Table 7.
Relationship between radiotherapy dose and time from treatment with frequency of morbidity by individual health domain among respondents
| Health domain | Radiotherapy dose, cGy | Time from treatment to questionnaire, y | ||||||
|---|---|---|---|---|---|---|---|---|
| No RT (n = 37) No. (%) | <3500 (n = 65) No. (%) | ≥3500 (n = 135) No. (%) | P* | ≤14 (n = 70) No. (%) | 15–23 (n = 85) No. (%) | >23 (n = 83) No. (%) | P* | |
| Vision | 5 (13.5) | 14 (21.5) | 26 (19.3) | .60 | 10 (14.3) | 14 (16.5) | 21 (25.3) | .08 |
| Hearing | 4 (10.8) | 8 (12.3) | 17 (12.6) | .79 | 4 (5.7) | 12 (14.1) | 13 (15.7) | .07 |
| Speech | 5 (13.5) | 19 (29.2) | 41 (30.4) | .08 | 13 (18.6) | 22 (25.9) | 30 (36.1) | .01 |
| Cardiovascular | 16 (43.2) | 38 (58.5) | 76 (56.3) | .27 | 28 (40.0) | 47 (55.3) | 55 (66.3) | .001 |
| Pulmonary | 5 (13.5) | 11 (16.9) | 35 (25.9) | .06 | 14 (20.0) | 18 (21.2) | 19 (22.9) | .66 |
| GI | 8 (21.6) | 17 (26.2) | 35 (25.9) | .66 | 12 (17.1) | 24 (28.2) | 24 (28.9) | .10 |
| GU | 0 (0.0) | 1 (1.5) | 3 (2.2) | .36 | 2 (2.9) | 0 (0.0) | 2 (2.4) | .89 |
| Musculoskeletal | 14 (37.8) | 29 (44.6) | 45 (33.3) | .33 | 15 (21.4) | 35 (41.2) | 38 (45.8) | .002 |
| Neurological | 4 (10.8) | 7 (10.7) | 12 (8.9) | .66 | 7 (10.0) | 7 (8.2) | 9 (10.8) | .84 |
| Endocrine | 12 (32.4) | 49 (75.4) | 101 (74.8) | <.001 | 35 (50.0) | 63 (74.1) | 65 (78.3) | <.001 |
| Psychiatric | 4 (10.8) | 11 (16.9) | 38 (28.2) | .01 | 14 (20.0) | 17 (20.0) | 22 (26.5) | .32 |
| Hematologic | 1 (2.7) | 4 (6.2) | 6 (4.4) | .85 | 1 (1.4) | 5 (5.9) | 5 (6.0) | .19 |
| Dermatologic | 5 (13.5) | 9 (13.9) | 40 (29.6) | .009 | 18 (25.7) | 17 (20.0) | 19 (22.9) | .71 |
| Infectious disease | 8 (21.6) | 23 (35.4) | 46 (34.1) | .25 | 18 (25.7) | 23 (27.1) | 36 (43.4) | .02 |
| Cancer | 7 (18.9) | 15 (23.1) | 33 (24.4) | .50 | 10 (14.3) | 20 (23.5) | 25 (30.1) | .02 |
* Mantel-Haenszel test for trend, two-sided.